Hide metadata

dc.date.accessioned2024-02-04T17:40:24Z
dc.date.available2024-02-04T17:40:24Z
dc.date.created2023-10-02T12:46:28Z
dc.date.issued2023
dc.identifier.citationLindemann, Kristina Yvonne Kathe Kleppe, Andreas Eyjólfsdóttir, Brynhildur Heimisdottir Danbolt, Svana Wang, Yun Yong Heli-Haugestøl, Anne Gjertine Walcott, Sara L Mjåland, Odd Navestad, Gerd-Anita Hermanrud, Silje Juul-Hansen, Knut Erling Kongsgaard, Ulf Erik . Prospective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer. International Journal of Gynecological Cancer. 2023, 33(8), 1279-1286
dc.identifier.urihttp://hdl.handle.net/10852/107472
dc.description.abstractObjective This prospective cohort study evaluated the introduction of an enhanced recovery after surgery (ERAS) pathway in a tertiary gynecologic oncology referral center. Compliance and clinical outcomes were studied in two separate surgical cohorts. Methods Patients undergoing laparotomy for suspected or verified advanced ovarian cancer at Oslo University Hospital were prospectively included in a pre- and post-implementation cohort. A priori, patients were stratified into: cohort 1, patients planned for surgery of advanced disease; and cohort 2, patients undergoing surgery for suspicious pelvic tumor. Baseline characteristics, adherence to the pathway, and clinical outcomes were assessed. Results Of the 439 included patients, 235 (54%) underwent surgery for advanced ovarian cancer in cohort 1 and 204 (46%) in cohort 2. In cohort 1, 53% of the patients underwent surgery with an intermediate/high Aletti complexity score. Post-ERAS, median fasting times for solids (13.1 hours post-ERAS vs 16.0 hours pre-ERAS, p<0.001) and fluids (3.7 hours post-ERAS vs 11.0 hours pre-ERAS, p<0.001) were significantly reduced. Peri-operative fluid management varied less and was reduced from median 15.8 mL/kg/hour (IQR 10.8–22.5) to 11.5 mL/kg/hour (IQR 9.0–15.4) (p<0.001). In cohort 2 only there was a statistically significant reduction in length of stay (mean (SD) 4.3±1.5 post-ERAS vs 4.6±1.2 pre-ERAS, p=0.026). Despite stable readmission rates, there were significantly more serious complications reported in cohort 1 post-ERAS. Conclusions ERAS increased adherence to current standards in peri-operative management with significant reduction in fasting times for both solids and fluids, and peri-operative fluid administration. Length of stay was reduced in patients with suspicious pelvic tumor. Despite serious complications being common in patients with advanced disease undergoing debulking surgery, a causal relationship with the ERAS protocol could not be established. Implementing ERAS and continuous performance auditing are crucial to advancing peri-operative care of patients with ovarian cancer.
dc.languageEN
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.titleProspective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer
dc.title.alternativeENEngelskEnglishProspective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer
dc.typeJournal article
dc.creator.authorLindemann, Kristina Yvonne Kathe
dc.creator.authorKleppe, Andreas
dc.creator.authorEyjólfsdóttir, Brynhildur
dc.creator.authorHeimisdottir Danbolt, Svana
dc.creator.authorWang, Yun Yong
dc.creator.authorHeli-Haugestøl, Anne Gjertine
dc.creator.authorWalcott, Sara L
dc.creator.authorMjåland, Odd
dc.creator.authorNavestad, Gerd-Anita
dc.creator.authorHermanrud, Silje
dc.creator.authorJuul-Hansen, Knut Erling
dc.creator.authorKongsgaard, Ulf Erik
cristin.unitcode185,53,49,14
cristin.unitnameAvdeling for gynekologisk kreft
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2180920
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International Journal of Gynecological Cancer&rft.volume=33&rft.spage=1279&rft.date=2023
dc.identifier.jtitleInternational Journal of Gynecological Cancer
dc.identifier.volume33
dc.identifier.issue8
dc.identifier.startpage1279
dc.identifier.endpage1286
dc.identifier.doihttps://doi.org/10.1136/ijgc-2023-004355
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1048-891X
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial 4.0 International
This item's license is: Attribution-NonCommercial 4.0 International